Q-omics provides the consensus-scored LUC7L profile across patient tissues and cancer cell-line models. LUC7L expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LUC7L is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, LUC7L protein abundance shows 19,964 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where LUC7L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LUC7L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LUC7L survival associations across molecular data types. LUC7L RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LUC7L RNA expression–survival associations across cancer types. High LUC7L expression shows unfavorable associations in KIRC, ACC, UVM and LIHC, but favorable associations in BLCA and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LUC7L RNA expression.
This table summarizes LUC7L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LUC7L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LUC7L shows higher tumor expression in COAD, LIHC, STAD, CHOL, KIRP and READ. The COAD box plot shows higher LUC7L RNA expression in tumor versus normal tissue (log2 FC = +1.081, t-test p < 0.001).
This table shows molecular features associated with LUC7L in patient tissues and cancer cell lines. In patient samples, LUC7L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LUC7L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
